Summary
Twenty-four patients with blastic-phase chronic myelogenous leukemia (CML) were treated with mitoxantrone. The patients included 19 whose cells were Philadelphia chromosome (Ph1+) and 5 who were either Ph1- or in whom cytogenetics were not available. Six of the 19 whose cells were Ph1+ responded and one of those who were Ph1- responded. The patients were further characterized into lymphoid or nonlymphoid on the basis of terminal deoxynucleotidyl transferase or morphology. Two of the patients with lymphoid transformation and 3 of those with nonlymphoid transformation responded. In 3 patients post-treatment cytogenetic evaluation revealed the presence of Ph1- metaphases. We conclude that mitoxantrone has modest activity in blCML and that the cytogenetic responses suggest the possibility of greater efficacy in chronic-phase CML.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Fefer A, Cheever MA, Greenberg PD, Applebaum FR, Boyd CN, Buckner CD, Kaplan HG, Ramberg R, Sanders JE, Storb R, Thomas ED (1982) Treatment of chronic granulocytic leukemia with chemoradiotherapy and transplantation of marrow from identical twins. N Engl J Med 306: 63
Talpaz M, McCredie KB, Mavligit GM, Gutterman JU (1983) Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 62: 689
Arlin ZA, Silver R, Cassileth S, Armentrout R, Gams R, Daghestani A, Coleman M, Schoch I, Dukart G (1985) Phase I–II trial of mitoxantrone in acute leukemia. Cancer Treat Rep 69: 61
Arlin ZA, Silver R, Cassileth P, Armentrout S, Gams R, Broun Jr G, Erslev A, Amare M, Moore J, Bertino J, Sartino G, Costanzi J, Dukart G, Schoch I (1985) Phase I–II trial of mitoxantrone in acute leukemia, interim report. Invest New Drugs (in press)
Schulman P, Van Echo D, Budman D, Ferrari A, Marks S, Wiernik P (1982) Phase II trial of mitoxantrone (DHD NSC 301739). Blastic phase in chronic myelogenous leukemia
Karanas A, Silver RT (1968) Characteristics of the terminal phase of chronic granulocytic leukemia. Blood 32: 445–459
Djaldetti M, Padeh B, Pinkhas J, DeVries A (1966) Prolonged remission in chronic myeloid leukemia after one course of busulfan. Blood 27: 103
Cunningham I, Gee T, Dowling M, Chaganti R, Bailey R, Hopfan S, Bowden L, Turnbull A, Knapper W, Clarkson B (1979) Results of treatment regimen (L-5 protocol). Blood 53: 375
Goto T, Nishikori M, Arlin ZA, Gee T, Kempin S, Burchenal J, Strife A, Wisniewski D, Lambek C, Little C, Jhanwar S, Chaganti R, Clarkson B (1982) Growth characteristics of leukemic and normal hematopoietic cells in Ph+ chronic myelogenous leukemia and effects of intensive treatment. Blood 59: 793
Jain K, Arlin ZA, Mertelsmann R, Gee T, Kempin S, Koziner B, Middleton A, Jhanwar S, Chaganti R, Clarkson B (1983) Philadelphia chromosome and terminal transferase-positive acute leukemia: similarity of terminal phase of chronic myelogenous leukemia and de novo acute presentation. J Clin Oncol 1: 669–675
Paciucci PA, Ohnuma T, Cuttner J, Silver RT, Holland JF (1983) Mitoxantrone in patients with acute leukemia in relapse. Cancer Res 43: 3919
Author information
Authors and Affiliations
Additional information
Supported in part by a grant from Lederle Laboratories and CA-34775
Rights and permissions
About this article
Cite this article
Arlin, Z.A., Berman, E., Jhanwar, S. et al. Treatment of blastic transformation of chronic myelogenous leukemia with mitoxantrone. Cancer Chemother. Pharmacol. 17, 189–190 (1986). https://doi.org/10.1007/BF00306753
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00306753